Rapport Therapeutics (NASDAQ:RAPP) COO Cheryl Gault Sells 10,000 Shares of Stock

Key Points

• COO Cheryl Gault sold 10,000 Rapport Therapeutics shares at an average price of $33.19, for total proceeds of $331,900. She retained 139,914 shares after the transaction, reducing her ownership by 6.67%.
• Rapport shares fell 2.3% to $32.83, while the company’s latest quarterly loss of $1.19 per share missed analyst expectations of a $1.12 loss.
• Despite the insider sale and recent stock decline, analysts remain broadly positive, with a consensus “Buy” rating and an average price target of $66.25.

Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) COO Cheryl Gault sold 10,000 shares of the stock in a transaction that occurred on Wednesday, September 30th. The shares were sold at an average price of $33.19, for a total value of $331,900.00. Following the sale, the chief operating officer directly owned 139,914 shares of the company's stock, valued at $4,643,745.66. The trade was a 6.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Rapport Therapeutics Stock Down 2.3%

RAPP stock traded down $0.77 during midday trading on Thursday, hitting $32.83. The company's stock had a trading volume of 326,569 shares, compared to its average volume of 359,106. The stock's 50-day moving average price is $43.95 and its 200 day moving average price is $38.95. Rapport Therapeutics, Inc. has a 1 year low of $23.75 and a 1 year high of $52.93. The stock has a market cap of $1.58 billion, a price-to-earnings ratio of -10.80 and a beta of 1.02.

Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($1.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.07). As a group, equities analysts forecast that Rapport Therapeutics, Inc. will post -4.09 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Rapport Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. KBC Group NV purchased a new stake in Rapport Therapeutics during the first quarter valued at about $30,000. State of Wyoming purchased a new position in shares of Rapport Therapeutics in the second quarter worth about $65,000. Meeder Asset Management Inc. purchased a new position in shares of Rapport Therapeutics in the second quarter worth about $116,000. AlphaCentric Advisors LLC increased its stake in shares of Rapport Therapeutics by 6.8% in the first quarter. AlphaCentric Advisors LLC now owns 6,438 shares of the company's stock worth $201,000 after purchasing an additional 408 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC bought a new stake in shares of Rapport Therapeutics in the first quarter valued at approximately $215,000.

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. Leerink Partners initiated coverage on shares of Rapport Therapeutics in a report on Wednesday, June 24th. They set an "outperform" rating and a $52.00 price objective for the company. William Blair began coverage on shares of Rapport Therapeutics in a research note on Tuesday, July 28th. They issued an "outperform" rating on the stock. HC Wainwright increased their target price on shares of Rapport Therapeutics from $40.00 to $66.00 and gave the company a "buy" rating in a research report on Wednesday, August 12th. UBS Group set a $80.00 price target on shares of Rapport Therapeutics in a research note on Wednesday, September 23rd. Finally, BTIG Research lifted their price target on shares of Rapport Therapeutics from $65.00 to $75.00 and gave the stock a "buy" rating in a report on Wednesday, September 16th. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Rapport Therapeutics has an average rating of "Buy" and a consensus price target of $66.25.

About Rapport Therapeutics

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for neurological and psychiatric disorders. The company uses its proprietary RAP platform to identify and target synaptic receptor-associated proteins, which can influence the activity, distribution and function of receptors involved in the central nervous system.

Rapport's lead clinical program is relutrigine, also known as RAP-219, an orally administered small-molecule therapy being developed for focal epilepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.